MDT
Fiscal year ends April Quarters are offset from the calendar — Q1 is May–Jul

Medtronic plc is a healthcare technology company founded in 1949 that develops, manufactures, and sells device-based medical therapies and services. The company operates through three primary reportable segments: the Cardiovascular Portfolio, the Neuroscience Portfolio, and the Medical Surgical Portfolio. In March 2026, Medtronic completed the separation of its Diabetes Business into a new independent, publicly traded company named MiniMed Group, Inc. The Cardiovascular Portfolio includes divisions for Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, and Coronary & Peripheral Vascular, offering products such as pacemakers, implantable cardioverter defibrillators, and transcatheter aortic valve replacement systems. The company serves healthcare systems, physicians, and patients globally. Medtronic utilizes artificial intelligence and data analytics to tailor therapies and facilitate remote monitoring. Notable product lines include the Micra transcatheter pacing system, the Evolut family of aortic valves, and the Affera ablation systems.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Medical Devices Homepage medtronic.com
Sector Healthcare IR page investorrelations.medtronic.com
Tags
cardiac rhythm management, structural heart, neuroscience, surgical robotics, diabetes care, remote monitoring, electrophysiology, spinal surgery, digestive health, respiratory care, MiniMed Group Inc., Micra, Azure, Adapta, Attesta, Aurora, Visia, Evera, Primo, Cobalt, Crome, Claria, Amplia, Compia, Percepta, Serena, Solara, PulseSelect, Affera, Arctic Front, Reveal LINQ, LINQ II, TYRX, CoreValve, Evolut PRO, Evolut PRO+, Evolut FX, Evolut FX+, Avalus Ultra, Endurant II, Endurant IIs, Valiant Captivia, Heli-FX, Harmony, Melody, Penditure, BlueSync, SelectSecure, Sprint Quattro, OmniaSecure, Prism, AccuRhythm
Press page —

Metrics

Valuation  
Market cap $ 122.244B
Market cap (USD) $ 122.244B
P/E 23.52
PEG 2.76
P/BV 2.43
P/S 3.26
P/OCF 15.21
P/FCF 19.94
Dividend yield 3.0%
Turnover / mcap —
Returns  
ROE 9.8%
ROI 6.2%
ROIC 6.6%
Profit margin 13.2%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 8.5%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity 56.4%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 24
Quality score 42.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Revenue 36.364B 33.537B 32.364B 31.227B 31.686B 30.117B 28.913B 30.557B 29.953B 29.71B 28.833B 20.261B 0
Net profit 4.801B 4.662B 3.676B 3.758B 5.039B 3.606B 4.789B 4.631B 3.104B 4.028B 3.538B 2.675B —
Free cash flow 5.426B 5.185B 5.2B 4.58B 5.978B 4.885B 6.021B 5.873B 3.616B 5.626B 4.172B 4.331B —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014
Share price 86.65 89.86 83.14 80.62 110.95 118.83 90.18 91.08 80.22 80.56 75.22 77.39 —
Price performance 12m -0.04 0.08 0.03 -0.27 -0.07 0.32 -0.01 0.14 -0 0.07 -0.03 0.26 —

Filed figures

Figure Apr 2017 Apr 2018 Apr 2019 Apr 2020 Apr 2021 Apr 2022 Apr 2023 Apr 2024 Apr 2025 Apr 2026
Balance sheet detail
Trade receivables (USD) 5.59B 5.99B 6.22B 4.65B 5.46B 5.55B 6B 6.13B 6.52B 6.64B
↳ YoY growth +0.5% +7.1% +3.9% -25.3% +17.6% +1.6% +8.1% +2.2% +6.3% +2.0%
↳ 5y CAGR +10.3% -1.9% -0.4% -0.1% +0.0% -0.3% +7.0% +4.0%
Borrowings, current (USD) 7.49B 2.06B 838M 2.78B 11M 3.74B 20M 1.07B 0.00 1.79B
Borrowings, non-current (USD) 25.9B 23.7B 24.6B 22.1B 26.4B 20.4B 24.3B 23.9B 25.6B 26.2B
Lease liabilities (USD) — — 1B 995M 1.09B 932M 1.11B 1.08B 1.17B 1.25B
Cash and deposits (USD) 4.97B 3.67B 4.39B 4.14B 3.59B 3.71B 1.54B 1.28B 2.22B 1.95B
Intangible assets (USD) 23.4B 21.7B 20.6B 19.1B 17.7B 15.6B 14.8B 13.2B 11.7B 10.1B
Right-of-use assets (USD) — — 1B 927M 998M 854M 1.04B 1.01B 1.1B 1.2B
Net debt (borrowings + leases - cash) (USD) 28.4B 22.1B 21B 21.8B 23.9B 21.3B 23.9B 24.8B 24.6B 27.3B
Cash flow detail
Operating cash flow (USD) 6.88B 4.68B 7.01B 7.23B 6.24B 7.35B 6.04B 6.79B 7.04B 7.33B
Purchases of property, plant and equipment (USD) -1.25B -1.07B -1.13B -1.21B -1.36B -1.37B -1.46B -1.59B -1.86B -1.9B
Change in receivables (cash effect) (USD) -75M -275M -581M 1.29B -761M -477M -576M -391M -433M -200M
Change in inventories (cash effect) (USD) -227M -192M -274M -577M 78M -560M -939M -139M -292M -404M
Change in payables (cash effect) (USD) 356M 65M 399M -44M 531M 213M 696M 391M 209M 46M
Dividends paid (cash effect) (USD) -2.38B -2.49B -2.69B -2.89B -3.12B -3.38B -3.62B -3.67B -3.59B -3.64B
Share buybacks (cash effect) (USD) -3.54B -2.17B -2.88B -1.33B -652M -2.54B -645M -2.14B -3.24B -1.04B
Interest paid (cash effect) (USD) -1.13B -1.15B -973M -643M -582M -540M -606M -826M -762M -774M
Income taxes paid (cash effect) (USD) -1.03B -2.54B -1.56B -878M -1.25B -996M -1.55B -1.62B -1.82B -1.94B
Share-based compensation (USD) 348M 344M 290M 297M 344M 359M 355M 393M 429M 457M
Operating cash flow before change in receivables (USD) 6.96B 4.96B 7.59B 5.94B 7B 7.82B 6.62B 7.18B 7.48B 7.53B
Free cash flow (OCF - PPE - intangibles) (USD) 5.63B 3.62B 5.87B 6.02B 4.89B 5.98B 4.58B 5.2B 5.19B 5.43B
Income detail
Research and development expense (USD) 2.19B 2.25B 2.33B 2.33B 2.49B 2.75B 2.7B 2.74B 2.73B 2.87B
↳ 5y CAGR +7.7% +9.5% +7.3% +2.3% +4.6% +3.7% +3.3% +3.2% +2.9%
Total comprehensive income (USD) 3.28B 4.13B 3.68B 3.96B 3.71B 6.27B 2.55B 3.88B 3.73B 5.02B
Comprehensive income to owners (USD) 3.28B 4.13B 3.66B 3.94B 3.68B 6.26B 2.52B 3.86B 3.7B 4.98B
Provision for credit losses (USD) 39M 52M 78M 99M 128M 58M 73M 90M 123M 136M
Credit cost ratio (credit losses / average receivables) (%) 0.7% 0.9% 1.3% 1.8% 2.5% 1.1% 1.3% 1.5% 1.9% 2.1%
Reported Jun 27, 2017 Jun 22, 2018 Jun 23, 2022 Jun 19, 2020 Jun 25, 2021 Jun 23, 2022 Jun 22, 2023 Jun 20, 2024 Jun 20, 2025 Jun 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

New education initiative aims to expand awareness of DBS and empower people with Parkinson's to make informed decisions about their treatment options GALWAY, Ireland and NEW YORK, Nov. 4, 2026...

New education initiative aims to expand awareness of DBS and empower people
with Parkinson's to make informed decisions about their treatment options

GALWAY, Ireland and NEW YORK, Nov. 4, 2026 /PRNewswire / -- Medtronic plc (NYSE: MDT) and The Michael J. Fox Foundation for Parkinson's Research  (MJFF) today announce a new educational initiative to help people with Parkinson's disease (PD) and their caregivers better understand deep brain stimulation (DBS), an established treatment option for managing certain symptoms of the disease.

Today, an estimated 6 million people worldwide live with PD, a number that is expected to double by 20401. While DBS has been used for nearly three decades to help manage some Parkinson's symptoms, awareness and understanding of the therapy remain important barriers to consideration. Together, MJFF and Medtronic aim to help close that knowledge gap, empowering more patients and families to explore their treatment options and have informed conversations with their care teams.

"Our urgent mission is to accelerate a cure for Parkinson's by advancing the most promising research. Partnerships with industry help us do more for people and families by expanding access to clear, practical resources that support informed decisions and meaningful participation in our mission," said Sohini Chowdhury, MJFF's chief program officer. "Together with Medtronic, we're creating robust educational materials to help people explore what DBS may offer and to keep them updated on the latest scientific progress."

Medtronic, the premier partner of MJFF's DBS education initiative, has supported DBS therapy for over 30 years and served more than 200,000 people with movement disorders and other conditions globally2. In 2025, the company introduced the world's first FDA-approved adaptive DBS system  for Parkinson's disease.

Through support from Medtronic, the Foundation will release educational materials to guide people considering DBS. Support from industry partners allows MJFF to maintain editorial oversight in the creation of high-quality resources, while directing donor-raised dollars toward critical research. A dedicated online hub, practical guide, interactive webinars and additional programming will provide accessible information about how DBS works, its potential benefits and risks, preparing for surgery, adjusting to life with a DBS device, and sharing the latest research advances. Resources are available today at michaeljfox.org/dbs , home of "The Live On with DBS Education Hub" powered by The Michael J. Fox Foundation. 

"Innovation can only make a difference if people know it exists," said Andrea Swain, president of Neuromodulation, part of the Medtronic Neuroscience portfolio. "Our responsibility extends beyond pioneering breakthrough technologies to helping more people understand the therapies available to them. By combining Medtronic's decades of DBS expertise with The Michael J. Fox Foundation's trusted connection to the Parkinson's community, we can help close a critical gap in therapy awareness."

**Helping more people understand their options
**Parkinson's is a progressive neurological disease that can affect movement, sleep, mood, cognition, and other functions. Symptoms and progression vary from person to person, and there is currently no cure or treatment proven to stop the disease's progression. As the number of people living with Parkinson's continues to grow, access to trusted information about available treatment options is increasingly important.

Often described as a cardiac pacemaker for the brain, DBS uses a surgically implanted device to deliver electrical signals to specific areas of the brain that control movement. Although DBS isn't appropriate for everyone with Parkinson's, it can help some people better manage their symptoms. DBS is used alongside medication, and some patients may be able to reduce their medication use.

"Living with Parkinson's has reminded me that no two days are alike. My experience with DBS the past five years has been meaningful; it's helped me stay connected to things I love, like being active with my family and friends," said John L. Lipp, writer, research advocate, participant in the ADAPT-PD (Adaptive DBS Algorithm for Personalized Therapy in Parkinson Disease) multi-center clinical trial, and person with Parkinson's. "I know firsthand what technology like this can mean for someone living with Parkinson's. But deciding whether DBS is right for you is a personal choice. People need clear information to understand what it may mean for them, weigh their options, and talk with their care team. I hope this initiative helps patients and families feel more prepared to have those conversations."

Since its inception in 2000, MJFF has funded more than $29 million in DBS research for Parkinson's. This work includes exploring new brain targets and improving technology to address more symptoms and enhance treatment experience. The Foundation also funds the Registry for the Advancement of Deep Brain Stimulation Therapy in Parkinson's Disease (RAD-PD), which collects clinician and patient data to help guide care decisions and improve understanding of DBS outcomes, settings, side effects and access.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com  and follow Medtronic on LinkedIn .

**Medtronic Media Contact:
**Naomi Rodiles
[email protected]

1-612-427-5521

**About The Michael J. Fox Foundation for Parkinson's Research (MJFF)
**As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors, and volunteers. In addition to funding $3 billion in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, MJFF forges groundbreaking collaborations, creates robust open-access data sets and biosample libraries with its landmark clinical study (PPMI), increases the flow of participants into Parkinson's disease clinical trials with its online tool (Fox Trial Finder), promotes Parkinson's awareness, and coordinates the grassroots involvement of thousands of Team Fox members around the world. For more information, visit us at www.michaeljfox.org , Facebook , Instagram  and LinkedIn .

MJFF Media Contact: Kristina Rodriguez
[email protected]

212-509-0995

  1. Dorsey ER, Sherer T, Okun MS, Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis. 2018;8(s1):S3-S8. doi:10.3233/JPD-181474.
  2. Medtronic data on file.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

SOURCE Medtronic plc

Engineering the extraordinary

Operational Headquarters 710 Medtronic Parkway, Minneapolis, MN 55432-5604 USA

L001-12022025: 2025-12

© 2026 Medtronic

(opens in a new window)

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 24, 2026, for its second quarter of fiscal year...

GALWAY, Ireland, Nov. 4, 2026 /PRNewswire / -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, November 24, 2026, for its second quarter of fiscal year 2027, which ended on Friday, October 30, 2026.

**About Medtronic
**Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn . 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results. 

Nearly nine out of 10 patients experienced a clinical benefit at six months Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical...

Nearly nine out of 10 patients experienced a clinical benefit at six months

Medtronic receives FDA approval for U.S. labeling update to Symplicity blood pressure procedure, expanding clinical evidence informing treatment options

GALWAY, Ireland and SAN DIEGO, Nov. 3, 2026 /PRNewswire / -- Medtronic plc, a global leader in healthcare technology, today announced primary endpoint results from the SPYRAL AFFIRM post-approval study of the Symplicity Spyral™ renal denervation (RDN) system. The study showed statistically significant and clinically meaningful blood pressure reductions at six months, including office, home, and 24-hour ambulatory blood pressure, with no increase in antihypertensive medications. The findings were presented as late-breaking data at the Transcatheter Cardiovascular Therapeutics (TCT) 2026 annual meeting and simultaneously published in Circulation Cardiovascular Interventions .

SPYRAL AFFIRM is a prospective, multicenter, single-arm study designed with the United States (U.S.) Food and Drug Administration (FDA) to provide real-world evidence in patients with uncontrolled hypertension treated in the U.S. across diverse patient populations and clinically relevant subgroups, including women, Black American and Hispanic patients, and patients 65 and older. Six-month results in the U.S. primary endpoint cohort were compared with a prespecified performance goal.

At six months, the data showed:

  • Patients treated with Symplicity Spyral had significant reductions in blood pressure compared with baseline:
    • Office Systolic Blood Pressure (OSBP): -18.2 ± 22.0 mmHg (p<0.0001)
    • Home blood pressure: -9.4 ± 13.8 mmHg (p<0.0001)
    • 24-hour Ambulatory Blood Pressure (ABPM): -9.7 ± 16.8 mmHg (p<0.0001)
  • Similar blood pressure reductions were demonstrated in women, Black American and Hispanic patients, and patients 65 and older
  • There was no increase in antihypertensive medications through six months (3.6 ± 2.0 medications, unchanged from baseline).
  • The composite safety endpoint occurred in 2.1% of patients
  • Nearly nine out of 10 patients experienced a clinical benefit at six months; a separate pooled analysis replicated this clinical benefit at three years.1

"The blood pressure reductions achieved with RDN in the AFFIRM study are transformative. In fact, they are within the range associated with a greater than 20% reduction in major adverse cardiovascular events, underscoring the clinical significance of these results," said Dr. David Kandzari, chief of Piedmont Heart Institute and Cardiovascular Services and lead principal investigator of the SPYRAL AFFIRM study. "Importantly, the study also demonstrated significant reductions in home blood pressure, offering insight into how patients are responding beyond the clinical setting and in their everyday lives. These findings reinforce the potential benefit of renal denervation in combination with lifestyle changes and medication for patients who continue to struggle with uncontrolled hypertension."

FDA approves Symplicity Spyral RDN system labeling update

Medtronic also announced it has received U.S. FDA approval to update the labeling for the Symplicity Spyral Multi-Electrode Renal Denervation Catheter. The updated labeling includes additional clinical data in patients with isolated systolic hypertension (ISH), chronic kidney disease (CKD) up to stage 3b (eGFR ≥30 mL/min/1.73 m²), and type 2 diabetes, expanding the clinical evidence available to help inform treatment decisions in these patient groups. The indication for use remains unchanged, allowing physicians and patients the full extent of options to manage their hypertension.

"Generating robust clinical evidence across broad and diverse patient populations remains central to our mission of improving outcomes for people living with hypertension," said Lara Barghout, senior vice president and president of Interventional Cardiology Therapies at Medtronic. "Backed by data from SPYRAL AFFIRM and our broader clinical program, this labeling update gives physicians additional information to guide treatment decisions for patients living with hypertension and high cardiovascular risk."

Evidence from the SPYRAL HTN clinical program, including SPYRAL AFFIRM and the Global SYMPLICITY Registry DEFINE, supported the labeling update.

The Symplicity RDN system is approved for commercial use in more than 80 countries around the world.  

**About Medtronic
**Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com  and follow Medtronic on LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Kandzari et al, EuroIntervention. 2026;22:e1-e1 published online March 2026. DOI: 10.4244/EIJ-D-26-00161

Contacts:
Lauren Mueller Doran Ingrid Goldberg
Public Relations Investor Relations
+1-763-285-9053 +1-763-505-2696

SOURCE Medtronic plc

Engineering the extraordinary

Operational Headquarters 710 Medtronic Parkway, Minneapolis, MN 55432-5604 USA

L001-12022025: 2025-12

© 2026 Medtronic

(opens in a new window)

Prompts

Medtronic plc. (ticker MDT), listed in United States.

Company History

Date Change Detail
Jul 28, 2016 Acquired Acquired Heartware International, Inc. (CIK 1389072). Its filings from before the deal are on its own company page, not shown here.
— Predecessor Predecessor Medtronic Inc (CIK 64670) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Medtronic plc.

ETF Weight in ETF Shares Market value As of
ABEQ 4.93% 88,582 $ 6.93M Jun 30, 2026
CAMX 3.61% 28,750 $ 2.455M Jul 31, 2026
ELCV 3.07% 90,286 $ 7.71M Jul 31, 2026
UDI 2.99% 1,554 $ 121.569K Jun 30, 2026
DIVP 2.98% 20,709 $ 1.62M Jun 30, 2026
AIVL 2.98% 158,315 $ 12.385M Jun 30, 2026
PAYR 2.92% 19,528 $ 1.667M Jul 31, 2026
GEND 2.79% 1,586 $ 135.429K Jul 31, 2026
MDLV 2.65% 12,508 $ 1.28M Nov 18, 2026
FDV 2.65% 273,149 $ 23.324M Jul 31, 2026
FLV 2.57% 108,264 $ 9.814M Aug 31, 2026
ESLV 2.55% 4,262 $ 363.932K Jul 31, 2026
DIVL 2.53% 19,436 $ 1.52M Jun 30, 2026
DIVS 2.13% 10,491 $ 820.711K Jun 30, 2026
HRTS 2.12% 13,029 $ 1.181M Aug 31, 2026
SWP 2.06% 34,133 $ 3.094M Aug 31, 2026
BLCV 1.65% 57,483 $ 5.914M Nov 16, 2026
LCF 1.63% 13,462 $ 1.053M Jun 30, 2026
DVND 1.55% 10,437 $ 816.487K Jun 30, 2026
ITAN 1.53% 18,462 $ 1.889M Nov 17, 2026
FEGE 1.45% 402,232 $ 36.462M Aug 31, 2026
AQEC 1.45% 106,259 $ 8.313M Jun 30, 2026
CGDV 1.41% 5,235,855 $ 538.665M Nov 16, 2026
SIXA 1.40% 78,651 $ 7.943M Nov 12, 2026
TCAL 1.32% 42,344 $ 4.356M Nov 17, 2026
CLCV 1.23% 2,462 $ 210.23K Jul 31, 2026
DIVD 1.19% 3,184 $ 330K Nov 18, 2026
CGVV 1.15% 22,627 $ 2.328M Nov 16, 2026
SFGV 1.12% 126,122 $ 12.9M Nov 18, 2026
CVAR 1.03% 5,189 $ 443.089K Jul 31, 2026
TIIV 0.99% 3,808 $ 325.165K Jul 31, 2026
ESUM 0.98% 20,963 $ 1.79M Jul 31, 2026
JDIV 0.87% 1,043 $ 106.72K Nov 17, 2026
CSTK 0.84% 17,345 $ 1.481M Jul 31, 2026
RJVI 0.84% 1,474 $ 115.311K Jun 30, 2026
LVDS 0.77% 8,997 $ 920.573K Nov 17, 2026
INCE 0.74% 12,000 $ 938.76K Jun 30, 2026
DYNF 0.73% 2,916,518 $ 300.051M Nov 16, 2026
LCDS 0.68% 1,055 $ 107.948K Nov 17, 2026
JOYT 0.66% 7,628 $ 780.497K Nov 17, 2026
JDOC 0.64% 622 $ 63.643K Nov 17, 2026
INRO 0.62% 35,417 $ 3.644M Nov 16, 2026
IALT 0.61% 469,058 $ 48.257M Nov 16, 2026
BKDV 0.58% 125,272 $ 10.697M Jul 31, 2026
BALI 0.58% 86,359 $ 8.885M Nov 16, 2026
INCM 0.57% 118,468 $ 9.268M Jun 30, 2026
VFVA 0.55% 57,783 $ 5.238M Aug 31, 2026
DFUV 0.52% 802,420 $ 81.036M Nov 12, 2026
INFO 0.50% 45,184 $ 4.648M Nov 13, 2026
GSPY 0.49% 32,701 $ 3.364M Nov 17, 2026
DFLV 0.49% 369,916 $ 37.358M Nov 12, 2026
DVAL 0.47% 4,375 $ 342.256K Jun 30, 2026
JEPI 0.47% 2,117,433 $ 216.656M Nov 17, 2026
HUSV 0.46% 2,586 $ 266.048K Nov 16, 2026
VFMV 0.44% 21,916 $ 1.987M Aug 31, 2026
TFPN 0.39% 5,901 $ 607.095K Nov 17, 2026
ESLG 0.38% 1,039 $ 88.72K Jul 31, 2026
HELO 0.38% 178,246 $ 18.238M Nov 17, 2026
JUSA 0.37% 31,985 $ 3.273M Nov 17, 2026
JHDV 0.35% 547 $ 42.792K Jun 30, 2026
XMAG 0.30% 6,349 $ 641.186K Nov 13, 2026
ACVF 0.24% 4,220 $ 360.346K Jul 31, 2026
LDRX 0.23% 6,376 $ 577.984K Aug 31, 2026
MODL 0.21% 28,018 $ 2.192M Jun 30, 2026
TACU 0.21% 374 $ 38.477K Nov 17, 2026
ACIO 0.21% 56,682 $ 4.84M Jul 31, 2026
ADME 0.21% 7,051 $ 602.085K Jul 31, 2026
JFLI 0.20% 924 $ 94.544K Nov 17, 2026
APUE 0.19% 51,809 $ 4.696M Aug 31, 2026
DFUS 0.19% 402,687 $ 40.667M Nov 12, 2026
SFTY 0.17% 15,188 $ 1.377M Aug 31, 2026
STOX 0.17% 4,307 $ 390.43K Aug 31, 2026
GEW 0.17% 2,724 $ 246.931K Aug 31, 2026
SIO 0.17% 5,776 $ 451.856K Jun 30, 2026
VOXP 0.17% 114 $ 9,734.46 Jul 31, 2026
DFSU 0.17% 39,636 $ 4.003M Nov 12, 2026
RAA 0.16% 12,337 $ 965.124K Jun 30, 2026
DFAU 0.16% 204,249 $ 20.627M Nov 12, 2026
AAUS 0.14% 6,827 $ 700K Nov 18, 2026
HCMT 0.14% 8,934 $ 762.874K Jul 31, 2026
AVSU 0.13% 6,035 $ 620.881K Nov 16, 2026
VSLU 0.12% 8,161 $ 638.435K Jun 30, 2026
MSLC 0.11% 49,503 $ 4.487M Aug 31, 2026
ENHU 0.11% 102 $ 10.494K Nov 16, 2026
AVLC 0.11% 16,295 $ 1.676M Nov 16, 2026
DFAC 0.11% 923,904 $ 93.305M Nov 12, 2026
IQSZ 0.11% 2,158 $ 184.272K Jul 31, 2026
DCOR 0.11% 468,837 $ 47.348M Nov 12, 2026
AVUS 0.10% 146,537 $ 15.076M Nov 16, 2026
DXUV 0.10% 59,654 $ 6.024M Nov 12, 2026
GVLU 0.09% 2,227 $ 229.114K Nov 17, 2026
YOKE 0.09% 2,042 $ 210K Nov 18, 2026
CSHP 0.07% 2,448 $ 251.85K Nov 16, 2026
LCTU 0.07% 8,017 $ 824.789K Nov 16, 2026
SEIV 0.07% 12,368 $ 967.549K Jun 30, 2026
NTSD 0.06% 291 $ 22.765K Jun 30, 2026
GDE 0.06% 2,944 $ 266.874K Aug 31, 2026
NTSX 0.05% 8,943 $ 699.611K Jun 30, 2026
LGDX 0.04% 541 $ 55.658K Nov 17, 2026
EBI 0.03% 2,124 $ 192.541K Aug 31, 2026